Učitavanje...
Expanding role of lenalidomide in hematologic malignancies
Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia...
Spremljeno u:
| Izdano u: | Cancer Manag Res |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4427066/ https://ncbi.nlm.nih.gov/pubmed/25999761 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S81310 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|